tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Tanabe K et al. Japanese single-center experience of kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119897
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Yamamoto S et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. 2005 Jan-Feb Transplant. Proc. pmid:15808570
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Ben-Ari Z et al. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. 2003 Transplant. Proc. pmid:12644067
Rafecas A et al. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation. 2002 Transplant. Proc. pmid:11959209
Lladó L et al. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation. 2002 Transplant. Proc. pmid:11959210
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Platz KP et al. FK506 for primary and rescue therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636570
Taibi A et al. Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. 1998 Transplant. Proc. pmid:9636571
Garcia C et al. Collaborative Brazilian Pediatric Renal Transplant Registry (CoBrazPed-RTx): A Report From 2004 to 2013. 2015 Transplant. Proc. pmid:26036492
Müller H et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. 2008 Transplant. Proc. pmid:18454992
Lo CM et al. More effective immunosuppression with the use of FK506 after liver transplantation. 2000 Transplant. Proc. pmid:11120161
Yeung S et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. 2004 Transplant. Proc. pmid:15518754
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Kim SJ et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. 2009 Transplant. Proc. pmid:19545705
Zhao J et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. 2009 Transplant. Proc. pmid:19545722
Sánchez-Lázaro IJ et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. 2010 Transplant. Proc. pmid:20970650
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Ziolkowski J et al. Effect of immunosuppressive regimen on acute rejection and liver graft function. 2003 Transplant. Proc. pmid:14529915
Fujisaki S et al. Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. 1994 Transplant. Proc. pmid:7518140
Teisseyre J et al. Elevated tacrolimus levels during diarrhea in children after liver transplantation. 2003 Transplant. Proc. pmid:14529919
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
Kato T et al. FK506 may suppress liver injury during the early period following living-related liver transplantation. 2003 Transplant. Proc. pmid:12591316
Takai K et al. Delayed graft function after renal transplantation from a non-heart-beating donors. 2003 Transplant. Proc. pmid:12591320
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Mayer AD Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. 2002 Transplant. Proc. pmid:12176452
Esposito C et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. 2004 Transplant. Proc. pmid:15110634
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Wlodarczyk Z et al. Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. 2005 Transplant. Proc. pmid:15919489
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Nanni G et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosupression. 2002 Transplant. Proc. pmid:12270323
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
Pape L et al. Long-term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12270367
Miyagi M et al. Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-beta expression. 2002 Transplant. Proc. pmid:12176497
Takayama J et al. Living related liver transplantation in patients with ABO incompatibility. 1998 Transplant. Proc. pmid:9838537
Wu MS et al. Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. 1998 Transplant. Proc. pmid:9838561
Scott JS et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? 1999 Feb-Mar Transplant. Proc. pmid:10083017
Meiser BM et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. 1999 Feb-Mar Transplant. Proc. pmid:10083018
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123103
Platz KP et al. Impact of immunosuppression and acute rejection on hepatitis B recurrence. 1997 Feb-Mar Transplant. Proc. pmid:9123107
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Okano K et al. Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. 1994 Transplant. Proc. pmid:7520635
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Baran DA et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. 2002 Transplant. Proc. pmid:12176547
Tsao CI et al. Unplanned readmission within 1 year after heart transplantation in Taiwan. 2010 Transplant. Proc. pmid:20430212
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Tsai SF et al. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database. 2012 Transplant. Proc. pmid:22310612
Batten P et al. Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. 1997 Feb-Mar Transplant. Proc. pmid:9123582
Nakao A et al. Cytokine mRNA expression on rat small bowel allograft treated with tacrolimus and simultaneous bone marrow transplantation via the portal vein. 2000 Transplant. Proc. pmid:10995965
Soltero L et al. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. 2003 Transplant. Proc. pmid:12826147
Yoshimura N et al. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation. 2016 Transplant. Proc. pmid:27234736
Langer RM et al. De novo tumors after kidney transplantation: the Budapest experience. 2003 Transplant. Proc. pmid:12826170
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
Glanemann M et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. 2000 Transplant. Proc. pmid:10812095
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
White SA et al. Randomized trial comparing neoral and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups. 2000 Transplant. Proc. pmid:10812132
Calne RY The development of immunosuppression: the rapamycin milestone. 2003 Transplant. Proc. pmid:12742463
Beckebaum S et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. 2004 Transplant. Proc. pmid:15621120
Burke GW et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. 2002 Transplant. Proc. pmid:12176628
Woeste G et al. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study. 2002 Transplant. Proc. pmid:12176629
Aguirrezabalaga J et al. Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. 2001 Feb-Mar Transplant. Proc. pmid:11267192
Shishido S et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267193
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Quijano Y et al. Tolerance: a study in long-term surviving animals after small bowel transplantation. 1998 Transplant. Proc. pmid:9745494
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Murase N et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. 1987 Transplant. Proc. pmid:2445081
Ybarra J et al. Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. 2003 Transplant. Proc. pmid:14697943
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Ito Y et al. Complete replacement of tracheal epithelia by the host promotes spontaneous acceptance of orthotopic tracheal allografts in rats. 2004 Transplant. Proc. pmid:15561264
Kiji T et al. Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. 2004 Transplant. Proc. pmid:15561265
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Mehra MR et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267438
Fujimura T et al. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636413
Kacar S et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. 2010 Transplant. Proc. pmid:21094806
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Boggi U et al. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750373
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510